Kornimate/medical-research-clean huggingface dataset:
reliability study using electrodermal activity to measure sensory processing in children with and without autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: the purpose of this study is ttho establish test-retest reliability of electrodermal markers used to quantify physiologic response to sensation using the sensory challenge protocol in children with and without autism spectrum disorder (asd).

this methodological research design is a prospective exploratory test-retest design assessing the use of electrodermal activity (eda) as an index of sensory processing. eda will be measured using skin conductance response (scr). the purpose of this study is to investigate if using eda is a reliable measure over time within the context of response to sensation. scores from test one and test two of each subject will be correlated to determine reliability of eda measure. reliability in this context will establish the utility of eda as an index of sensory processing. testing will occur two times within a six week period.

Eligibility criteria:
inclusion criteria: boys ages 4 - 11 years old. * able to sit for 30 minutes and follow simple directions. * children with confirmed autism spectrum disorder via school records or parent report. * typically developing children free of medical or neurological conditions exclusion criteria: * medical or neurological conditions other than autism. * hearing loss or visual impairments. * children taking medications known to affect arousal. * children who are not able to follow simple commands.
comparison of serum trefoil factor 3 in patients with gingivitis and periodontitis after scaling and root planing

Conditions: Gingivitis and Periodontal Diseases

Summary: this study is intended to measure serum trefoil factor 3 at baseline and 3 months after, following nonsurgical periodontal therapy in patients with gingivitis and chronic periodontitis.

a goal of periodontal diagnostic procedure is to provide useful information to the clinician regarding the present periodontal disease type and severity. advances in diagnostic research are moving towards methods where periodontal risk can be identified and quantified by objective measures such as biomarkers. trefoil factors (tffs) are one such secreted molecules derived from mucin producing epithelial cells of the gastro intestinal tracts and other tissues such as salivary glands, parotid ducts and oral mucosa. among three trefoil factors reported, trefoil factor 3 (tff3) is the modifying factor for signalling pathway involved in cell survival, cell proliferation and cell migration of oral keratinocytes. hence assessing the marker levels would achieve beneficial effects on diagnosing the disease severity.

Eligibility criteria:
inclusion criteria: for gingivitis: * gingival index: 1.1 to 2. * modifies plaque index: 1.0 to 1.9 for periodontitis: * gingival index: 1.1 to 2. * modifies plaque index: 1.0 to 1.9 * probing depth \> 4mm * clinical attachment loss \> 2mm exclusion criteria: for gingivitis: * presence of gingival recession. * presence of clinical attachment loss. * presence of furcation. * presence of systemic infections like diabetes, infections. * smokers. * antibiotic therapy received preceding 3 months. * patients who underwent periodontal therapy within 3 months. * pregnant and lactating women. for periodontitis: * presence of any systemic conditions like diabetes, infections. * smokers. * antibiotic therapy received preceding 3 months. * patients who underwent periodontal therapy within 3 months. * pregnant and lactating women.
effectiveness study on fosinopril and/or losartan in patients with chronic kidney disease stage 3

Conditions: Chronic Kidney Insufficiency; Angiotensin-Converting Enzyme Inhibitors; Angiotensin II Type 1 Receptor Blockers; Proteinuria

Summary: the purpose of this study is to determine whether fosinopril and losartan are effective in the treatment of patients with chronic kidney disease(ckd) stage 3.


Eligibility criteria:
inclusion criteria: * patients aged 18-75 years old * roll out secondary renal diseases * do not use steroids and immunosuppresive drugs * acei/arb treated patients should have 7-14 days wash out period，sidbp\< 110mmhg * willing and able to comprehend and give written informed consent * willing to follow-up regularly exclusion criteria: * use steroids and immunosuppresive drugs * secondary renal diseases * acute cardio-cerebral diseases within 6 months * post renal transplantation * pregnant/nursing women * history of hypersensitivity to acei/arb * refuse to join clinical trial
the prevalence of iron deficiency and the effectiveness of ferinject® in patients with hfpef (id-hfpef)

Conditions: Chronic Heart Failure; Iron Deficiency, Latent

Summary: observational cohort randomized controlled study to study the influence of correction of id by intravenous injection of ferric carboxymaltose (ferinject®) on quality of life indicators, functional status in a cohort of patients with hfpef.

the prevalence of hfpef among patients admitted to cardiology hospitals will be studied. the study will include patients with nyha ii-iii who have signed an informed consent that meets the inclusion/exclusion criteria. the effectiveness of intravenous administration of iron carboxymaltose (ferinject ® ) to correct iron deficiency and improve the clinical course of hfpef will be evaluated. a group without iron deficiency will be recruited as a control group (n=30).

Eligibility criteria:
inclusion criteria: * signed informed consent to participate in the study; * in new york heart association (nyha) ii-iii functional class due to stable symptomatic chronic heart failure (chf); * left ventricular ejection fraction (lvef) ≥50%; objective signs of structural and/or functional disorders of the heart consistent with the presence of lv diastolic dysfunction/increased lv filling pressure, including elevated levels of natriuretic peptide; * screening ferritin below 100 µg/l, or below 300 µg/l when transferrin saturation (tsat) is below 20%; * screening haemoglobin (hb) at the time of switching on ( 90-150 g/l). exclusion criteria: * uncontrolled arterial hypertension; * аnemia not related to iron deficiency; * аnemia with a hemoglobin level of less than 90 g/l; * less than 1 year after acute myocardial infarction; * less than 1 year after acute cerebral circulation disorder; * less than 1 year after surgical interventions, including non-cardiac operations and myocardial revascularization (coronary bypass surgery, coronary artery stenting), operations for valvular pathology; * chronic alcoholism (including alcoholic heart disease), mental disorders; * severe hepatic (increased transaminase levels above the upper three limits of normal) and renal insufficiency (glomerular filtration rate less than 15 ml/min/1.73 m2); * known active infection, clinically significant bleeding, active malignancy; * severe autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc.); * severe bronchial asthma, copd in the acute stage; * allergic reactions to medications in the anamnesis, eczema, atopic allergic reaction; * blood transfusions and taking erythropoiesis-stimulating drugs during the previous three months.

Keywords: hfpef iron deficiency ferric carboxymaltose ferinject
a multi-center study of short and long-term use of protopic ointment in patients with atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: the purpose of the study is to determine the impact of topical corticosteroids on the safety and effectiveness of protopic ointment in the short-term treatment of moderate to severe atopic dermatitis and to compare the safety and effectiveness of protopic ointment to placebo in the long-term management of atopic dermatitis

study includes an interim short-term, open label period. patients could also receive a second course of open label treatment dependent on disease exacerbation.

Eligibility criteria:
inclusion criteria: * patient must have atopic dermatitis * patient must be at least 2 years of age exclusion criteria: * patient is pregnant or breast feeding an infant

Keywords: treatment effectiveness treatment efficacy immunomodulator, topical tacrolimus, topical dermatitis, atopic eczema, atopic atopic dermatitis
oculomotor and spatial cognition deficits in schizophrenia

Conditions: Schizophrenia

Summary: description: (verbatim from the applicant's abstract) abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia. however, the regional disturbances in brain function causing these deficits are not yet known. this application proposes a series of integrated behavioral studies designed to identify causes of deficits in schizophrenia.

we will be assessing clinical symptoms and cognition before and after treatment.

Eligibility criteria:
inclusion criteria: * inclusion criteria: inclusion criteria for this study are (1) able and willing to give written informed consent; (2) no contraindications to mri (cardiac pacemaker, aneurysm clip, cochlear implants, iud, shrapnel, history of metal fragments in eyes, neurostimulators or other metal devices, weight of 250lbs or more, claustrophobia) and (3) medically stable. sedation will not be used for mri studies because cooperation is essential. exclusion criteria: * any subject is excluded from the imaging studies if they have any contraindications to mri such as cardiac pacemaker, aneurysm clip, cochlear implants, pregnancy in the later stages (because of body size and limited comfort for mri studies), iud, shrapnel, history of metal fragments in eyes, neurostimulators, weight of 250 lbs. or more, or claustrophobia. individuals with mental retardation, neurologic disease or significant medical illness that might effect neuronal or vascular physiology will not be recruited.

Keywords: schizophrenia antipsychotic risperidone
safety and efficacy of cariprazine for mania

Conditions: Bipolar Disorder; Mania

Summary: the objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine monotherapy versus placebo for the treatment of acute manic or mixed episodes associated with bipolar i disorder.


Eligibility criteria:
inclusion criteria: * patients who have provided informed consent prior to any study specific procedures * patients currently meeting the diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) criteria for bipolar i disorder, as confirmed by the structured clinical interview for diagnostic and statistical manual of mental disorders, fourth edition (scid) manic or mixed type with or without psychotic symptoms * voluntarily hospitalized for current manic episode * patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ecg) exclusion criteria: * patients with a dsm-iv-tr diagnosis of an axis i disorder other than bipolar i disorder that was the primary focus of treatment within the previous six months

Keywords: acute mania bipolar i disorder
a randomised study of levitra to treat men with erections problems and previously untreated with similar therapy.

Conditions: Erectile Dysfunction

Summary: the objective of this study was to evaluate the efficacy and tolerability of the phosphodiesterase type 5 inhibitor (pde5 inhibitor), vardenafil, in a broad population of subjects with erectile dysfunction of different aetiologies and severity, who have not been previously treated with a pde5 inhibitor; efficacy and safety was compared with placebo.


Eligibility criteria:
inclusion criteria: * males with erectile dysfunction according to the national institute of health (nih) consensus statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance * heterosexual relationship for more than 6 months * partner willing to complete the tss exclusion criteria: * primary hypoactive sexual desire * history of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months * nitrate use * other exclusion criteria apply according to the summary of product characteristics

Keywords: erectile dysfunction pde5 inhibitors
the study to evaluate the safety and efficacy of the onyx family

Conditions: Coronary Artery Disease

Summary: observation of the safety and efficacy of 1-month dual antiplatelet therapy (dapt) after percutaneous coronary intervention using onyx family stents in elderly patients aged 75 years or older

for elderly patients aged 75 years or older undergoing percutaneous coronary intervention with onyx family drug-eluting stents, observe the safety and efficacy of transitioning from dual antiplatelet therapy to single therapy for one year after one month of dual antiplatelet therapy

Eligibility criteria:
inclusion criteria: * aged 75 or more. * eligible for interventional procedures. * evidence of myocardial ischemia or coronary artery stenosis ≥ 50%. * able to take antiplatelets for at least 1 months after the procedure. * patients who underwent coronary artery procedures with zes (medtronic, minneapolis, mn, onyx™ family) stent. exclusion criteria: * the patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, zotarolimus, and contrast media (patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \[eg, rash\] may be enrolled. those with true anaphylaxis to prior contrast media, however, should not be enrolled). * patients with active pathologic bleeding. * gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months. * history of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia). * noncardiac comorbid conditions are present with life expectancy \&lt;1 year or that may result in protocol noncompliance (per site investigator\&#39;s medical judgment). * patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
evaluation of the index of sexual life questionnaire

Conditions: Impotence

Summary: the purpose of the study is to assess the sensibility of the isl questionnaire.


Eligibility criteria:
inclusion criteria: ed patient must: * be male, 18 years of age with no upper age limit; * have a documented clinical diagnosis of erectile dysfunction confirmed by an erectile function (iief) score 25. erectile dysfunction is defined as "the inability to achieve and/or maintain an erection of the penis sufficient to permit satisfactory sexual performance" (impotence-nih consensus conference, jama 1993, 270: 83-90); * have a stable female partner for at least 6 months prior to screening. exclusion criteria: * have a known hypersensitivity to sildenafil or any component of the study medication; medical history of treatment-related intolerable side effects to sildenafil * be currently prescribed, taking and/or likely to be treated with nitrates or nitric oxide donors in any form on either a regular or intermittent basis.
evd drainage data and intracranial pressure (icp) measurements

Conditions: Hydrocephalus

Summary: rhaeos, inc. is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (csf). implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. there is no technology available today that can easily assess csf flow in shunts wirelessly, bedside, and without capital equipment until now. flowsense, is a wireless, noninvasive thermal flow sensor that can be mounted on a patient's neck overlying the shunt to detect the presence and magnitude of csf. similar in size to a bandage, it is composed of soft, silicone with no hard edges. data is wirelessly transmitted to a custom designed mobile app. with flowsense, monitoring of shunt function can occur in clinics, in-patient settings, and emergency departments, thereby reducing unnecessary imaging, hospital length of stay, and readmission costs.

hydrocephalus is caused by excess cerebrospinal fluid in the brain that can lead to lethargy, seizures, and comas. there is no cure for it nor is there any way to prevent it from happening. affecting 1m americans today, treatment costs the healthcare system \>$2b per year. neurosurgically implanted shunts, the standard treatment, often fail. patients with failed shunts show nonspecific symptoms, including headaches, dizziness and nausea. cts and mris are used for diagnosis, but are inconclusive, expensive, and often lead to unnecessary admissions. rhaeos, inc. is a vc backed, clinical stage medical device company developing flowsense, a patent protected platform technology and a noninvasive wireless, wearable skin patch that can assess and monitor fluid flow subdermally throughout the body. the company is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (csf). implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. there is no technology available today that can easily assess csf flow in shunts wirelessly, bedside, and without capital equipment until now. flowsense, is a wireless, noninvasive thermal flow sensor that can be mounted on a patient¿s neck overlying the shunt to detect the presence and magnitude of csf. similar in size to a bandage, it is composed of soft, silicone with no hard edges. data is wirelessly transmitted to a custom designed mobile app. with flowsense, monitoring of shunt function can occur in clinics, in-patient settings, and emergency departments, thereby reducing unnecessary imaging, hospital length of stay, and readmission costs.

Eligibility criteria:
inclusion criteria: * patients with one or more existing external ventricular drains (evds). exclusion criteria: * patients with no external ventricular drains (evds).

Keywords: evd shunt hydrocephalus
effect of smartphone addiction on myoelectrical activity of sternocleidomastoid muscle in adult

Conditions: Heavy Smart Phone Users

Summary: this study will be conducted to identify the effect of smartphone addiction myoelectrical activity on sternocleidomastoid in adults by measuring the amplitude of emg signals of the sternocleidomastoid muscle in adults and root mean square of emg signals of the sternocleidomastoid muscle in adults


Eligibility criteria:
inclusion criteria: * subject's age range from 18-30 years old * all participants use the same smartphone with a touch screen of 6,7 inches. exclusion criteria: * neck pain ( spondylosis, spondylolysis) * systemic diseases. * spinal deviation
reverberation effects on med-el recipients

Conditions: Hearing Loss, Sensorineural

Summary: the purpose of this study is to investigate speech understanding in simulated reverberant environments with med-el cochlear implant recipients.

the study will determine if electrode length and coding strategy effect performance. the investigator will also study performance over time with new recipients.

Eligibility criteria:
inclusion criteria: * med-el current cochlear implant recipients of the flex 24 or 28 will be included * minimum of 6 months experience with their cochlear implant * minimum of 10 new adult med-el recipients of the flex 24 or flex 28 electrodes * patient at the university of miami exclusion criteria: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers)
genotyping fcɣrs genes of hiv-1 patients "progressor": correlation with the changing profile of the infection

Conditions: HIV Infection

Summary: this non-interventional study aims to determine whether there is a correlation between the fc receptor polymorphism (fcr) and the course of the disease following hiv infection.


Eligibility criteria:
inclusion criteria: * patient aged 18 or older, * patient affiliated to a social security scheme, * informed consent dated and signed by the investigating physician the patient, * patients infected with hiv-1 having progressed in clinical (stage c) or biologically (cd4 nadir \ 10,000 copies / ml) exclusion criteria: * impossibility of giving the subject informed information (subject in an emergency situation, difficulty in understanding the subject, ...) * subject under safeguard of justice, * subject under tutelage or under curatorship,

Keywords: hiv infection fc receptor polymorphism (fcr)
effects of constraint-induced movement therapy with home-based hand-arm bimanual intensive therapy in children with unilateral cerebral palsy

Conditions: Cerebral Palsy, Spastic Hemiplegic

Summary: this study evaluates the therapeutic effects of constraint-induced movement therapy (cimt) with home-based hand-arm bimanual intensive therapy (h-habit) with unilateral cerebral palsy. half of the participants will receive cimt and h-habit and others will only receive cimt.


Eligibility criteria:
inclusion criteria: * age 4 to 12 years * macs level 1-3 * diagnosed with unilateral cp due to central nervous system lesions exclusion criteria: * severe cognitive dysfunction that rendered them unable to perform simple tasks (e.g., reaching, grasping * untreated seizures * visual or auditory problems interfering with treatment * prior history of musculoskeletal disorders. * macs level 4-5

Keywords: constraint-induced movement therapy home-based hand-arm bimanual intensive therapy unilateral cerebral palsy
an analysis of presentation and outcome following treatment of pancreatic endocrine neoplasms

Conditions: Pancreatic Endocrine Neoplasms

Summary: a single institutional study of pancreatic endocrine neoplasms over 18 years.

the investigators did an analysis from a prospectively maintained database of patients who underwent pancreatic resections or nonresective procedures for neoplasms of the pancreas at sir ganga ram hospital from 1995 to 2013 and using pathological reports and preoperative ct scan as the gold standard, the investigators identified 40 patients with pens.

Eligibility criteria:
inclusion criteria: * pathological reports and prooperative cat scan showing endocrine pancreatic tumours exclusion criteria: * nonendocrine pancreatic tumours

Keywords: endocrine pancreas pancreatic endocrine neoplasm